NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

InflaRx N.V (NASDAQ: IFRX)

 
IFRX Technical Analysis
4
As on 9th Jun 2023 IFRX STOCK Price closed @ 4.16 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 2.43 & Buy for SHORT-TERM with Stoploss of 3.60 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

IFRXSTOCK Price

Open 4.04 Change Price %
High 4.18 1 Day 0.16 4.00
Low 4.02 1 Week -0.03 -0.72
Close 4.16 1 Month -0.49 -10.54
Volume 174961 1 Year -0.38 -8.37
52 Week High 6.10 | 52 Week Low 0.78
 
NASDAQ USA Most Active Stocks
TSLA 244.40 4.06%
TTOO 0.07 -12.50%
SOFI 8.18 0.74%
FFIE 0.33 6.45%
PONO 1.72 2.38%
AMD 124.92 3.20%
IDEX 0.06 0.00%
NKLA 0.70 14.75%
AMZN 123.43 -0.66%
AAPL 180.96 0.22%
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
METXW 0.05 150.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
JCIC 22.08 116.68%
AURCW 0.04 100.00%
NOVVW 0.02 100.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
PTIXW 0.01 -66.67%
AGBAW 0.02 -66.67%
MLACW 0.02 -60.00%
MILEW 0.06 -53.85%
RCRTW 0.02 -50.00%
LOTZW 0.01 -50.00%
GSMGW 0.01 -50.00%
DKDCW 0.01 -50.00%
 
 
IFRX
Daily Charts
IFRX
Intraday Charts
Whats New @
Bazaartrend
IFRX
Free Analysis
 
IFRX Important Levels Intraday
RESISTANCE4.47
RESISTANCE4.37
RESISTANCE4.31
RESISTANCE4.25
SUPPORT4.07
SUPPORT4.01
SUPPORT3.95
SUPPORT3.85
 
IFRX Forecast May 2024
4th UP Forecast6.95
3rd UP Forecast6.06
2nd UP Forecast5.5
1st UP Forecast4.95
1st DOWN Forecast3.37
2nd DOWN Forecast2.82
3rd DOWN Forecast2.26
4th DOWN Forecast1.37
 
IFRX Weekly Forecast
4th UP Forecast5.89
3rd UP Forecast5.34
2nd UP Forecast4.99
1st UP Forecast4.65
1st DOWN Forecast3.67
2nd DOWN Forecast3.33
3rd DOWN Forecast2.98
4th DOWN Forecast2.43
 
IFRX Forecast2024
4th UP Forecast16.63
3rd UP Forecast12.63
2nd UP Forecast10.16
1st UP Forecast7.69
1st DOWN Forecast0.63
2nd DOWN Forecast-1.84
3rd DOWN Forecast-4.31
4th DOWN Forecast-8.31
 
 
IFRX Other Details
Segment EQ
Market Capital 180721968.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
IFRX Address
IFRX
 
IFRX Latest News
 
Your Comments and Response on InflaRx N.V
 
IFRX Business Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Address: Winzerlaer Str. 2, Jena, Germany, 07745
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service